Incyte Corporation
LSE: 0J9P.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- William J. Meury
- Employees
- 2,617
- Headquarters
- Wilmington, United States
- IPO year
- 2018
- Market cap
- $20.0B
- Website
- https://www.incyte.com
Loading 0J9P…
Loading profile data…Frequently asked questions about 0J9P
What does Incyte Corporation (0J9P.L) do?
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as...
Where does 0J9P.L trade?
Incyte Corporation (0J9P.L) trades on the London Stock Exchange.
What sector is 0J9P.L in?
Incyte Corporation (0J9P.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Incyte Corporation?
William J. Meury is the chief executive officer of Incyte Corporation (0J9P.L).
Where is Incyte Corporation headquartered?
Incyte Corporation is headquartered in United States.
Does 0J9P.L pay a dividend?
Incyte Corporation (0J9P.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0J9P.L go public?
Incyte Corporation (0J9P.L) completed its initial public offering in 2018.